Compare PMTS & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | TNXP |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.1M | 197.9M |
| IPO Year | 2015 | N/A |
| Metric | PMTS | TNXP |
|---|---|---|
| Price | $14.12 | $19.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $32.00 | ★ $70.00 |
| AVG Volume (30 Days) | 50.0K | ★ 807.7K |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.20 | N/A |
| Revenue | ★ $515,576,000.00 | $10,299,000.00 |
| Revenue This Year | $14.84 | $14.79 |
| Revenue Next Year | $10.55 | $933.49 |
| P/E Ratio | $11.82 | ★ N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $11.64 | $6.76 |
| 52 Week High | $35.19 | $130.00 |
| Indicator | PMTS | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 54.04 | 58.73 |
| Support Level | $13.03 | $15.10 |
| Resistance Level | $14.36 | $16.18 |
| Average True Range (ATR) | 0.64 | 1.39 |
| MACD | 0.26 | 0.61 |
| Stochastic Oscillator | 96.70 | 92.10 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.